Cargando…

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib

Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor‐positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miettinen, Teemu P, Peltier, Julien, Härtlova, Anetta, Gierliński, Marek, Jansen, Valerie M, Trost, Matthias, Björklund, Mikael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978322/ https://www.ncbi.nlm.nih.gov/pubmed/29669860 http://dx.doi.org/10.15252/embj.201798359

Ejemplares similares

High‐resolution quantitative proteome analysis reveals substantial differences between phagosomes of RAW 264.7 and bone marrow derived macrophages
por: Guo, Manman, et al.
Publicado: (2015)

Quantitative Proteome Analysis of Temporally Resolved Phagosomes Following Uptake Via Key Phagocytic Receptors
por: Dill, Brian D., et al.
Publicado: (2015)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Mevalonate Pathway Regulates Cell Size Homeostasis and Proteostasis through Autophagy
por: Miettinen, Teemu P., et al.
Publicado: (2015)

Modified ribosome profiling reveals high abundance of ribosome protected mRNA fragments derived from 3′ untranslated regions
por: Miettinen, Teemu P., et al.
Publicado: (2015)

NQO2 Is a Reactive Oxygen Species Generating Off-Target for Acetaminophen
por: Miettinen, Teemu P., et al.
Publicado: (2014)

Cellular Allometry of Mitochondrial Functionality Establishes the Optimal Cell Size
por: Miettinen, Teemu P., et al.
Publicado: (2016)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

TPL‐2 kinase induces phagosome acidification to promote macrophage killing of bacteria
por: Breyer, Felix, et al.
Publicado: (2021)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Triggering MSR1 promotes JNK‐mediated inflammation in IL‐4‐activated macrophages
por: Guo, Manman, et al.
Publicado: (2019)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

The E3 ubiquitin ligase RNF115 regulates phagosome maturation and host response to bacterial infection
por: Bilkei‐Gorzo, Orsolya, et al.
Publicado: (2022)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
por: Bollard, Julien, et al.
Publicado: (2017)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023)

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
por: Pennycook, Betheney R., et al.
Publicado: (2021)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
por: Böhm, Michael J., et al.
Publicado: (2019)

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
por: Hsieh, Feng‐Shu, et al.
Publicado: (2017)

Proteomics characterisation of the L929 cell supernatant and its role in BMDM differentiation
por: Heap, Rachel E, et al.
Publicado: (2021)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
por: Bonuccelli, Gloria, et al.
Publicado: (2016)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
por: Bandiera, Carole, et al.
Publicado: (2023)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

CDK4/6 Inhibitor Palbociclib Amplifies the Radiosensitivity to Nasopharyngeal Carcinoma Cells via Mediating Apoptosis and Suppressing DNA Damage Repair
por: Xie, Xianhe, et al.
Publicado: (2019)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
por: Qin, Qiong, et al.
Publicado: (2020)

LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages
por: Härtlova, Anetta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3im2nddj8ueh1unb0ssv5cvpd0